CompletedPhase 1NCT03452332
Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers
Studying Vaginal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Lilie L LinM.D. Anderson Cancer Center
- Intervention
- Durvalumab(biological)
- Enrollment
- 20 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2018 – 2023
Study locations (2)
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, United States
- M D Anderson Cancer Center, Houston, Texas, United States
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03452332 on ClinicalTrials.govOther trials for Vaginal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07407647Vaginal DHEA to Improve Vaginal Health After Radiation for Women With Gynecologic, Anal or Rectal CancerOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06686043HPV Vaccine, Imiquimod, and Metformin Combination TrialBaylor College of Medicine
- ACTIVE NOT RECRUITINGNCT04713618Changes in Pelvic Health, Sexual Function, and Quality of Life in Women With Pelvic Cancer Undergoing Radiation TherapyOhio State University Comprehensive Cancer Center
- ACTIVE NOT RECRUITINGNCT00791635Longitudinal Evaluation of Women Undergoing Pelvic Surgery for the Treatment of Gynecologic CancerM.D. Anderson Cancer Center